Category - Developments

Developments

Titan Pharma to sell certain ProNeura assets

Titan Pharmaceuticals (NASDAQ:TTNP) entered into an asset purchase agreement with Fedson for the sale of certain ProNeura assets, including Titan’s portfolio of drug addiction products, in addition to other early...

July 27, 2023

Developments

Carmell to merge with Axoloti Biologix

Carmell Therapeutics (NASDAQ:CTCX) signed a definitive agreement and plan of merger with Axoloti Biologix, a profitable regenerative medicine company developing products for active soft tissue repair, aesthetics and...

July 27, 2023

Developments

Humacyte completes Phase 2/3 enrollment in vascular trauma repair

Humacyte (NASDAQ:HUMA) completed enrollment of its Phase 2/3 vascular trauma trial that is expected to support a BLA filing for Humacyte’s human acellular vessel (HAV) in vascular trauma repair planned for the fourth...

July 26, 2023

Developments

Symetryx ups offer for Check-Cap to $4.60 a share

Closely-held Symetryx increased its non-binding proposal to acquire Check-Cap (NASDAQ:CHEK) to $4.60 a share from $4.35 when it announced its offer on July 18. At last report, Check-Cap had 5.8 million shares...

July 25, 2023

Developments

Enzo sells clinical laboratory to Labcorp for $113.25-million

Enzo Biochem (NYSE:ENZ) closed a transaction to sell certain assets of Enzo’s clinical laboratory division (Enzo Clinical Labs) to Laboratory Corp. of America Holdings (NYSE:LH) for $113.25-million. In accordance with...

July 25, 2023

Developments

IntelGenx updates Montelukast VersaFilm collaboration for Parkinson’s

IntelGenx (TSX:IGX; OTCQB:IGXT) finalized a research grant agreement with Sweden’s Karolinska University Hospital and that the manufacturing of both active and placebo films are underway for a planned multicentre...

July 25, 2023

Developments

Infinity terminates merger accord with MEI Pharma

Infinity Pharmaceuticals (NASDAQ:INFI) terminated its merger agreement to merge with MEI Pharma (NASDAQ:MEIP). At a special meeting of MEI stockholders on July 23, MEI did not obtain stockholder approval for the merger...

July 24, 2023

Developments

Axxess acquires Complia Health

Axxess, a home healthcare technology provider, acquired Complia Health in move that adds more clients, more talent and even greater engagement with leading care providers among the Axxess family. Complia’s roster of...

July 24, 2023

Developments

Advent nabs rare pediatric disease designation for bronchopulmonary dysplasia in preemies

Advent Therapeutics received FDA rare pediatric disease designation for its vitamin A metabolic and reparative respiratory drugs for the prevention of bronchopulmonary dysplasia (BPD) in premature infants. BPD is a rare...

July 20, 2023

Developments

Eliem Therapeutics to explore strategic alternatives

Eliem Therapeutics (NASDAQ:ELYM) completed a review of its business, including the status of its programs, resources, and capabilities, and has decided to halt further development of its Kv7 program and to conduct a...

July 20, 2023

Category - Developments

Titan Pharma to sell certain ProNeura assets

Carmell to merge with Axoloti Biologix

Humacyte completes Phase 2/3 enrollment in vascular trauma repair

Symetryx ups offer for Check-Cap to $4.60 a share

Enzo sells clinical laboratory to Labcorp for $113.25-million

IntelGenx updates Montelukast VersaFilm collaboration for Parkinson’s

Infinity terminates merger accord with MEI Pharma

Axxess acquires Complia Health

Advent nabs rare pediatric disease designation for bronchopulmonary dysplasia in preemies

Eliem Therapeutics to explore strategic alternatives

General

More